Company Info

Board of Directors

Jerome B. Zeldis, M.D., Ph.D.

Chairman of the Board

Dr. Zeldis was appointed as a member and Vice Chairman of our board of directors effective as of April 25, 2016 and as Chairman of the Board effective as of May 5, 2017. Dr. Zeldis is the Chief Medical Officer and President of Clinical Research at Sorrento Therapeutics, Inc. Previously, Dr. Zeldis was CEO of Celgene Global Health and Chief Medical Officer of Celgene Corporation, Summit, NJ, until June 2016. Prior to that he was Celgene’s Senior Vice President of Clinical Research and Medical Affairs and has been at Celgene since February 1997. He attended Brown University for an A.B., M.S., followed by Yale University for an M.Phil., M.D., Ph.D. in Molecular Biophysics and Biochemistry (immunochemistry). Dr. Zeldis trained in Internal Medicine at the UCLA Center for the Health Sciences and Gastroenterology at the Massachusetts General Hospital and Harvard Medical School. He was Assistant Professor of Medicine at the Harvard Medical School, Associate Professor of Medicine at University of California, Davis, Clinical Associate Professor of Medicine at Cornell Medical School and Professor of Clinical Medicine at the Robert Wood Johnson Medical School in New Brunswick, New Jersey. Prior to working at Celgene, Dr. Zeldis worked at Sandoz Research Institute and Janssen Research Institute in both clinical research and medical development. He has been a board member of a few start-up biotechnology companies and is currently Chairman of the board of Alliqua and Trek Therapeutics in addition to board positions at PTC Therapeutics and Soligenix. He has published 122 peer reviewed articles and is the named inventor on 43 U.S. patents.

Douglas A. Hamilton

President, Chief Executive Officer and Director

Mr. Hamilton was appointed as President and Chief Executive Officer on June 17, 2015 and elected as a director effective May 5, 2017. Mr. Hamilton consulted for us as acting Chief Financial Officer since August 2014. Mr. Hamilton has over 20 years experience in the life-sciences industry with broad domain expertise including financial management, management consulting, venture capital, and R&D operations management. Previously he served as CFO for SEA Medical Systems, a Silicon Valley health-tech company. In 2007, Mr. Hamilton founded and serves as Partner at New Biology Ventures, a life-sciences incubator accelerator and consulting firm. From 1999 to 2006, Mr. Hamilton served as CFO and COO for Javelin Pharmaceuticals, a commercial stage pharmaceutical company focused on the development and commercialization of a portfolio of acute pain medications. While at Javelin, Mr. Hamilton helped build a late stage product pipeline, took the company public, and raised over $82 million in financing. Prior to Javelin, Mr. Hamilton was the CFO and Director of Business Development for PolaRx Biopharmaceuticals, Inc. At PolaRx he helped developed the orphan drug Trisenox® and co-led the $45.2 million merger with Cell Therapeutics (currently owned by Teva Pharmaceuticals). Mr. Hamilton served as Project Manager for the Vfend® and Zithromax® product teams at Pfizer, in addition to the Aranesp®, Epogen®, Stemgen®, MGDF, and Cell Therapy product development teams at Amgen. Prior to Amgen, Mr. Hamilton served in the sales and marketing group at Pharmacia Biotech (now GE Healthcare Life Sciences), and in the recombinant DNA vaccine research group at Connaught Laboratories (now Sanofi-Pasteur). Mr. Hamilton earned his honors Bachelor of Science degree from the Department of Medical Genetics at the University of Toronto and his MBA from the Ivey Business School at Western University.

Paul Billings, M.D., Ph.D.


Dr. Billings was appointed to our board of directors effective as of May 24, 2017. Dr. Billings is a board certified internist and clinical geneticist. Dr. Billings is currently a partner at the Bethesda Group Fund L.P., a position he has held since January 2016. From January 2015 to January 2016, Dr. Billings served as Executive-in-Residence at the California Innovation Center of Johnson and Johnson, Inc. He has also served as the Medical Director of the IMPACT program at Thermo Fisher Scientific, Inc. (TFS) from 2013 to 2015. From 2010 to 2014, he served as the first and only Chief Medical Officer at Life Technologies Corporation (which was acquired by TFS), and the Genetic Sciences Division of TFS. Dr. Billings currently serves on the board of directors of Trovagene, Inc. since October 2013, and Rennova Health, Inc. (formerly CollabRx, Inc.) since November 2015. Dr. Billings has previously served as a director of Inc. from February 2012 to May 2013. He serves as an advisor or director for many companies, including Fabric Genomics, Inc. (formerly Omicia, Inc.), BioScale Inc., Applied Immunology, Inc., Aueon, Inc. and PAX Neuroscience Inc. He held senior management positions at Cord Blood Registry, Inc., GeneSage, Inc., Laboratory Corporation of America Holdings (LabCorp), and CELLective DX Corporation. Dr. Billings’ clinical experience includes senior administrative positions at El Camino Hospital and the Veteran’s Administration and he served as a physician at many medical centers. He has held numerous academic appointments at prestigious universities including Harvard University, Stanford University, U.C. Berkeley, and U.C. San Francisco. He is a prolific author with nearly 200 publications and books on genomic medicine. Dr. Billings holds an M.D. from Harvard Medical School and a Ph.D. in immunology, also from Harvard University.